“Dream with Ryvu” – a corporate movie by Ryvu Therapeutics

Read More

Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

Read More

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

Read More

Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

Read More

Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

Read More

Ryvu Therapeutics Reports Q3 2020 Financial Results

Read More

Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

Read More

Ryvu Therapeutics at BIO-Europe 2020

Read More

Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

Read More

First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

Read More